Sernova’s Cell Pouch System tackles diabetes
Sernova Corp. is a Canadian-based clinical-stage biotechnology company that is developing its Cell Pouch System.
This is a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A.
On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression.
In May 2022, the company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2).
Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.
We spoke with Philip Toleikis, president and CEO of Sernova at Bio-Europe in Leipzig, Germany.
➡ Subscribe to our newsletter: https://bit.ly/3kHyfKc
➡ Get more biotech news:
Official site: https://bit.ly/3OJgYzi
Linkedin: / 5312453
Twitter: / labiotech_eu
Facebook: / labiotech.eu
Instagram: / labiotech.eu
About Labiotech.eu:
Labiotech.eu is an online publication covering the global biotech industry, with a mix of news and in-depth analysis. Updated daily, the site also includes a weekly podcast.
@sernovacorp.1312
#biotech #medicaldevice #diabetes #hemophilia #thyroid